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A novel murine model of non-typable Haemophilus influenzae (NTHi) 
pneumonia was established. A plastic tube was inserted into the trachea 7 days before 
bacterial inoculation. Numbers of NTHi recovered from the lungs and trachea were 
maintainedfor 7 days. Histologically, bronchioles and adjacent alveoli in the intubation 
group were filled with numerous inflammatory cells. Additionally, we evaluated the 
efficacy of sitafloxacin compared to ciprofloxacin using our new murine pneumonia 
model. Our data suggest that sitafloxacin displays equivalent efficacy to ciprofloxacin 
against H. influenzae pneumonia. Our new murine NTHi pneumonia model appears 
useful not only for in vivo evaluation of antibiotics, but also for analysis of the 
pathogenesis of H. influenzae pneumonia. 
 




Haemophilus influenzae is recognized as a frequent cause of a variety of infections, 
including acute otitis media, sinusitis, acute purulent exacerbation of chronic bronchitis 
and pneumonia. With the recent overuse of antibiotics such as cephalosporin, the 
incidence of drug-resistant H. influenzae in Japan has been increasing steadily, 
particularly for β-lactamase-negative, ampicillin-resistant H. influenzae (BLNAR). 
Clinically, we have encountered H. influenzae pneumonia in patients with chronic 
respiratory diseases such as bronchiectasis, diffuse panbronchiolitis and cystic fibrosis. 
Murine models of H. influenzae pneumonia have been reported using agar beads and 
cell-bound organisms1-5. We describe herein a novel murine model of NTHi pneumonia 
that uses an indwelling intratracheal tube to escape from the normal host defense 
mechanisms and cause pulmonary infection. We also evaluated the in vivo efficacies of 
sitafloxacin, a new fluoroquinolone, using this new murine model.  
 




NTHi strain ATCC51907, which had been stored in tripticase soy broth with 10% 
glycerol stocks maintained at -80 °C, was spread on chocolate α agar plates (Nissui 
Pharmaceutical, Tokyo, Japan) and incubated overnight (18-24 h) at 37 °C in 5% CO2.  
 
Laboratory animals 
Six-week-old male ddY-specific pathogen-free mice (body weight, 16-20 g) were 
purchased from SLC Japan (Tokyo, Japan). All animals were housed in a pathogen-free 
environment and received sterile food and water in the Laboratory Animal Center for 
Biomedical Science at Nagasaki University (Nagasaki, Japan). Experimental protocols 
were approved by the Ethics Review Committee for Animal Experimentation at 
Nagasaki University. 
 
Murine model of H. influenzae respiratory infection 
We used as reference the intubation model of chronic airway infection in mice using the 
methods described by Yanagihara et al6 (Fig. 1). Briefly, disposable, sterile, plastic 
cut-down intravenous catheters (3-Fr, 1.0-mm diameter; Atom, Tokyo, Japan) were 
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used for tracheal intubation. Tubes were 3.0 mm in length, with slits at the proximal end 
to prevent blockage by oral secretions. The intubation procedure was performed under 
pentobarbital anesthesia. The blunted end of the inner needle of an intravenous catheter 
(Angiocath; Becton Dickinson Vascular Access, Sandy, UT, USA) was inserted through 
the oral cavity with the outer sheath and attached tube at the tip. The tube was advanced 
through the vocal cords into the trachea. The inner needle was then removed, and the 
outer sheath was gently pushed to place the plastic tube into the main bronchus. The 
intubation model in this study is different from the reference (6) from the timing of 
inoculation. Unfortunately, we could not establish the pneumonia by using the bacterial 
precoated tube preparing just like reference (6). For the purpose of impairment the 
bronchial surface and the delay in bacterial clearance, organisms were instilled 7 days 
after intubation. H. influenzae were cultured on chocolate Ⅱ agar plates (Nissui 
Pharmaceutical) and incubated overnight (18-24 h) at 37 °C in 5% CO2, then the 
organisms were suspended in normal saline. Final numbers of bacteria prepared were 
approximately 2×109 colony-forming units (cfu)/ml, as determined by the optical 
density method. Infection was induced by intratracheally inoculation of 0.05 ml of 




Bacteriological and histopathological examination 
Mice were divided into 3 groups: mice that were inoculated with H. influenzae after 
intubation; mice that were not intubated and only inoculated with H. influenzae; and 
mice that were intubated without inoculation. Non-intubated group was inoculated 
intratracheally at the same time when the intubated group was inoculated 7 days after 
intubation. Mice were sacrificed on days 1, 3, 5 and 7 after inoculation. The tube was 
removed and the lungs were excised under aseptic conditions when mice were sacrificed. 
Lungs were homogenized in 1.0 ml of phosphate-buffered saline and cultured 
quantitatively by serial dilution on chocolate α agar plates (Nissui Pharmaceutical), then 
incubated overnight (18-24 h) at 37 °C in 5% CO2. For histopathological examinations, 
lung specimens were fixed in 10% formalin-buffered solution.  
 
Bronchoalveolar lavage and cytokine enzyme-linked immunosorbent assay 
(ELISA) 
Bronchoalveolar lavage (BAL) was performed as described previously7. Briefly, mice 
(n=10, each groups) were sacrificed on day 1, 3, 5 or 7 after inoculation. The chest was 
opened to expose the lungs and a disposable sterile plastic cutdown intravenous catheter 
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was inserted into the trachea. The intratracheal tube was not removed for BAL 
procedure. BAL was performed 3 times sequentially using 1.0 ml of saline each time. 
Recovered fluid fractions were pooled for each animal. Total cell counts were 
performed by Turk staining. For differential cell counts, cells were centrifuged at 850 
rpm for 2 min onto slides, which were then stained with Diff-Quick stain. Differential 
cell counts were performed by counting 100 cells. Concentrations of macrophage 
inflammatory protein (MIP)-2 and interleukin (IL)-1β in BAL fluid (BALF) were 




Sitafloxacin (STFX) was kindly provided by Daiichi-Sankyo (Tokyo, Japan), and 
ciprofloxacin (CPFX) was kindly provided by Bayer Corporation (Tokyo, Japan). These 
agents were prepared according to the instructions of the manufacturer and frozen at 




Antibiotic susceptibility testing 
Susceptibilities of H. influenzae to sitafloxacin and ciprofloxacin were tested in 
duplicate for each isolates at inocula of 105 cfu/ml and determined using a broth dilution 
method with Haemophilus Test Medium according to Clinical and Laboratory 
Standards Institute (CLSI) recommendations8. 
 
Antibiotics examinations 
From 24 h after infection, antibiotics were administered orally twice a day to the STFX 
treatment group and CPFX treatment group for 3 days. Each single dose was 10 mg/kg9. 
Each group was killed by cervical dislocation 12 h after the last drug administration. 






Data are expressed as the mean ± standard error of the mean (SEM). Differences 
between numbers of viable bacteria in lungs were evaluated by analysis of variance. 
Values of P<0.05 were considered statistically significant. 
 
RESULTS 
In vitro susceptibility 
For H. influenzae ATCC51907, minimum inhibitory concentrations (MICs) of STFX, 
and CPFX were 0.0006 mg/L and 0.003 mg/L, respectively. Both antimicrobial agents 
showed good potency against H. influenzae according to CLSI recommendations. 
 
Changes in viable bacterial number over time (Fig. 2) 
Respiratory infection occurred in all intubated mice with inoculation. The number of 
viable bacteria increased to 7.1±1.0 (log10 cfu/ml) 3 days after inoculation. Conversely, 
the number of viable bacterial decreased immediately and no colonies were isolated by 





Total cell counts (Table 1A) and neutrophil counts (Table 1B) were significantly higher 
in intubated mice than in non-intubated mice after inoculation. Peak total cell counts 
and neutrophil counts were seen on day 1 after inoculation and gradually decreased in 
intubated group. To estimate further differences, inflammatory cytokine levels in BALF 
were analyzed. MIP-2 (Table 2A), IL-1β (Table 2B) were significantly higher in 
intubated mice than in non-intubated mice after inoculation. These data imply that the 
acute inflammation induced by H. influenzae was strongest in the early days of infection 
and can persist for 7 days in intubated mice. Total cell counts, neutrophil counts and 
inflammatory cytokines increased slightly with intubation alone (data not shown).  
 
Histopathological examination 
In mice infected with intratracheal tube, bronchioles and adjacent alveoli were filled 
with numerous neutrophils and epithelial cells, and invasion of inflammatory cells 
occurred on day 1 and persisted to day 7 after infection (Fig. 3A-D). The inflammatory 
changes were shown in both lungs. Conversely, in non-intubated infected mice, mild 
inflammatory changes were evident on day 1 after infection, but inflammation was 
greatly improved by day 3 (Fig. 3E-H). Intubation alone did not produce inflammatory 
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changes in the mouse lung. 
In vivo efficacy of STFX against H. influenzae 
We divided into 3 groups to estimate the in vivo efficacy of STFX using this new 
murine H. influenzae pneumonia model; mice that were untreated; mice were treated by 
STFX; mice that were treated by CPFX; and all mice were intubated and inoculated. In 
the bacteriological study, mean viable bacterial counts in the lungs of STFX- and 
CPFX-treated mice and untreated control mice were 1.8±0.4 log10 cfu/ml, 1.9±0.3 log10 
cfu/ml and 7.3 ±0.4 log10 cfu/ml at 3 days after administration of antimicrobial agents, 
respectively. STFX and CPFX each completely eradicated viable bacteria from all 
mouse lungs (Fig. 4A). Histopathological studies of lung tissue from control mice 
showed the presence of progressive pneumonia (Fig. 5A). In mice with antimicrobial 
therapy, total cell counts and neutrophil counts in BALF decreased (Figs. 4B, 4C). In 
addition, only a small number of neutrophils were seen in alveolar walls, and 
inflammatory changes were apparently improved (Figs. 5B, 5C). These data confirmed 






H. influenzae is a frequent pulmonary pathogen in humans, causing 
community-acquired infections such as chronic bronchitis, pneumonia, meningitis and 
sinusitis1,10-12. Despite the high case-fatality rates reported for acute and chronic H. 
influenzae infection, little information on pathogenesis and therapy has been gained 
from experimental models. Although murine models of H. influenzae infection have 
been created using agar beads and cell-bound organisms, few reports have described 
experimental models1-5. These methods were established to prevent rapid removal by 
mucociliary clearance and examined the reasons for the characteristics of H. influenzae 
pneumonia induced by microaspiration of the intracellular bacteria. Clinically, H. 
influenzae pneumonia is well known to arise in patients who have chronic pulmonary 
diseases such as chronic obstructive pulmonary disease or bronchiectasis15,16. The 
present study established a new murine model of H. influenzae pneumonia using a 
sterile intratracheal indwelling catheter. Intratracheal tube was removed when mice 
were sacrificed under aseptic conditions, and H. influenzae was isolated from the 
removed tube (3.2±1.0 log10 cfu/ml). Since this model contributed to semipermanent 
escape from the normal host defense mechanisms for the pathogens, and caused lower 
respiratory tract infection. In this model, an intratracheal tube is essential for induction 
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of pneumonia. We inoculated bacteria 7 days after intubation, because we expected the 
impairment of the bronchial surface and the delay in bacterial clearance. In addition, 
although histopathological findings in the lungs of animals intubated with sterile tubes 
showed localized inflammation close to the site of tube attachment (data not shown), we 
expected mucociliary clearance in the airways would be impaired by the plastic tube. 
Moreover, this method implied that bacteria could persist for a long period in the 
airways because of the protective environment of the intratracheal tube. In our study, 
many viable bacteria could be recovered from the respiratory tract for 7 days. These 
data indicate that pretreatment with an intratracheal tube plays an important role in 
allowing H. influenzae to persist in the lower respiratory tract for a long period. 
Histopathologically, in non-intubated mice, mild inflammatory changes were seen on 
day 1, but improved immediately by day 3. In addition, in intubated mice, the high 
amounts of cytokine (MIP-2 and IL-1β) were released into the BALF although we 
didn’t analyze the protease-level. This improvement is presumably facilitated by the 
rapid clearance of bacteria from the airways in the absence of intubation.  
The current study also illustrated the utility of this new experimental model in 
evaluating therapeutic efficacy. In comparison with controls, antibiotic-treated mice 
showed significantly improved bacterial clearance from the lungs and trachea (Fig. 4). 
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Several experimental studies have suggested that CPFX and other quinolones are 
therapeutically active in the treatment of respiratory infection17. Sitafloxacin is a new 
fluoroquinolone offering a broader spectrum and more potent activity against 
gram-positive, gram-negative and atypical pathogens than other quinolones such as 
ofloxacin (OFLX), ciprofloxacin (CPFX) and sparafloxacin (SPFX)18,19. The in vivo 
activity of STFX against H. influenzae was compared to that of CPFX, through the 
evaluation of BALF analysis and bacteriological and histopathological changes (Figs. 4 
and 5). In STFX-treated mice, H. influenzae was decreased by 3 days after starting oral 
administration of STFX (Fig. 4A). In addition, total cell counts and neutrophil counts in 
BALF were considerably decreased, and histopathologically, inflammatory changes 
were greatly improved with STFX treatment (Figs. 4 and 5). These results resembled 
those for CPFX. There are some considerable reasons. First, in present study, we used 
the immunocompetent, healty mice, and the fluoroquinolone well-susceptible strain. We 
consider that if the mice had the destroyed lung or the bacteria was drug resistant strains, 
STFX may be able to show the effectiveness better than CPFX because it was reported 
that STFX could show the higher tissue concentration than CPFX9. Second, it is also 
considered that the drug levels of STFX and CPFX, respectively, in lung-tissue of mice 
may be different from the human origin so that the differences could not be shown in 
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this study.  
In conclusion, we demonstrated that STFX offers a high degree of efficacy against H. 
influenzae using our new murine model of H. influenzae pneumonia. We expect that our 
newly established model will have wide potential use as an animal model of H. 
influenzae to investigate not only the efficacy of antibiotics, but also the pathogenesis of 
H. influenzae. 
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Figure 1: Schematic of the intubation tube and intubation procedure in the mouse 
bronchus. 
Figure 2: Number of viable organisms in lower respiratory organs. Mice were 
inoculated with 1×108 cfu/ml of H. influenzae ATCC51907. On days 1, 3, 5 and 7 after 
infection, numbers of viable bacteria were isolated, but in the non-intubated group, 
complete eradication was achieved within 5 days. *P<0.001 compared with the 
non-intubated group. ●, Intubated group; ■, Non-intubated group. 
 
Figure 3: High-power magnification of the lung (×200, hematoxylin and eosin). A-D) 
Intubated group; E-H) Non-intubated group. A, E) Day 1; B, F) Day 3; C, G) Day 5; D, 
H) Day 7. In intubated mice that were infected, bronchioles and alveoli were filled with 
neutrophils from day 1 to day 7 after infection. 
 
Figure 4: Viable bacteria (A) were completely eradicated by 3 days after starting oral 
STFX or CPFX administration. Total cell counts (B) and neutrophil counts (C) in BALF 
were markedly decreased by 3 days after beginning oral STFX or CPFX administration. 
*P<0.05 compared with control group. STFX, oral administration, 10 mg/kg, twice/day; 
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CPFX, oral administration, 10 mg/kg, twice/day. 
Figure 5: High-power magnification of the lung after 3 days treatment (×200, 
hematoxylin and eosin). (A) Control, untreated; (B) STFX group, oral administration, 
10 mg/kg, twice/day; (C) CPFX group, oral administration, 10 mg/kg, twice/day. 
Inflammatory changes improved immediately after starting treatment in STFX and 
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Infectious days 
Figure 2
Total cell counts in BALF (×106)
Table 1A: Serial changes in total cell counts in BALF*
Day
      















Table 1B: Serial changes in number of neutrophils in BALF*
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*Values are expressed as mean±SD. 
* * p<0.01 compared with non-intubation group. 
MIP-2 (pg/ml) 




































*Values are expressed as mean±SD. 
* * p<0.01 compared with non-intubation group.
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